{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:10:10Z","timestamp":1784549410122,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2026.111004","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:13:34Z","timestamp":1770970414000},"page":"111004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical stage IIA\/B embryonal carcinoma predominant nonseminomatous germ cell tumor: Minimizing treatment burden"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1097-3020","authenticated-orcid":false,"given":"Jiping","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Thakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Masterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Adra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Cary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.111004_bib0001","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMra1407550","article-title":"Testicular cancer: discoveries and updates","volume":"371","author":"Hanna","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.111004_bib0002","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2024.27122","article-title":"Testicular germ cell tumors: a review","volume":"333","author":"Singla","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2026.111004_bib0003","doi-asserted-by":"crossref","first-page":"687.e13","DOI":"10.1016\/j.urolonc.2020.03.014","article-title":"National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy","volume":"38","author":"Labbate","year":"2020","journal-title":"Urol Oncol: Sem Origin Investig"},{"key":"10.1016\/j.urolonc.2026.111004_bib0004","first-page":"167","article-title":"Testicular cancer in 2023: current status and recent progress","volume":"74","author":"McHugh","year":"2024","journal-title":"CA: Cancer J Clinic"},{"key":"10.1016\/j.urolonc.2026.111004_bib0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/PAS.0000000000000171","article-title":"Testicular embryonal carcinoma: a morphologic study of 180 cases highlighting unusual and unemphasized aspects","volume":"38","author":"Kao","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0006","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/01.ju.0000101513.64777.f2","article-title":"A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only","volume":"171","author":"Nicolai","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0007","unstructured":"National Comprehensive Cancer Network. Testicular cancer (Version 1.2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/testicular.pdf. Accessed March 16, 2025."},{"key":"10.1016\/j.urolonc.2026.111004_bib0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/JU.0000000000003694","article-title":"Diagnosis and treatment of early-stage testicular cancer: AUA Guideline Amendment 2023","volume":"211","author":"Stephenson","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0009","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2000.18.2.358","article-title":"Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma\u2013predominant testis cancer","volume":"18","author":"Sweeney","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0010","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0022-5347(05)67528-3","article-title":"Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection","volume":"163","author":"Hermans","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/JU.0000000000000792","article-title":"Long-term oncologic outcomes after primary retroperitoneal lymph node dissection: minimizing the need for adjuvant chemotherapy","volume":"204","author":"Douglawi","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0012","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1200\/JCO.22.00118","article-title":"Primary retroperitoneal lymph node dissection for patients with pathologic stage II nonseminomatous germ cell tumor-N1, N2, and N3 disease: is adjuvant chemotherapy necessary?","volume":"40","author":"Tachibana","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0013","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.ju.0000165163.03805.37","article-title":"Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and\/or lymphovascular invasion","volume":"174","author":"Stephenson","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0014","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/01.ju.0000181810.22617.f8","article-title":"Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia","volume":"174","author":"Al-Tourah","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ucl.2024.03.009","article-title":"Retroperitoneal lymph node dissection: perioperative management and updates on surgical techniques","volume":"51","author":"Zeng","year":"2024","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.urolonc.2026.111004_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6783147","article-title":"The use of modified templates in early and advanced stage nonseminomatous germ cell tumor","volume":"2018","author":"Masterson","year":"2018","journal-title":"Adv Urol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0017","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1159\/000020197","article-title":"RPLND or primary chemotherapy in clinical stage IIA\/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment","volume":"37","author":"Weissbach","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0018","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdt493","article-title":"What are the indications for postchemotherapy retroperitoneal lymph node dissection?","volume":"25","author":"Einhorn","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.111004_bib0019","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.euo.2019.06.007","article-title":"Nationwide patterns of care for stage II nonseminomatous germ cell tumor of the testicle","volume":"3","author":"Ghandour","year":"2020","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:52:26Z","timestamp":1784548346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078143926000153"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical stage IIA\/B embryonal carcinoma predominant nonseminomatous germ cell tumor: Minimizing treatment burden","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111004"}}